We are upgrading the repository! A content freeze has been extended to December 11, 2024, when we expect the new repository to become available. New submissions or changes to existing items will not be allowed until after the new website goes live. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorChang, Tamara Y.
dc.contributor.authorJaffray, Julie
dc.contributor.authorWoda, Bruce A.
dc.contributor.authorNewburger, Peter E.
dc.contributor.authorUsmani, G. Naheed
dc.date2022-08-11T08:10:10.000
dc.date.accessioned2022-08-23T16:58:16Z
dc.date.available2022-08-23T16:58:16Z
dc.date.issued2010-12-15
dc.date.submitted2012-04-25
dc.identifier.citation2010 Dec 15. <a href="http://dx.doi.org/10.1002/pbc.22846">Link to article on publisher's website</a>
dc.identifier.issn1545-5009 (Linking)
dc.identifier.doi10.1002/pbc.22846
dc.identifier.pmid21370424
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43331
dc.description.abstractHemophagocytic lymphohistiocytosis (HLH) is a rare histiocytic reactive process due to mutations in the perforin, MUNC13-4 or syntaxin 11 genes, or secondary to malignancy, infection or autoimmune disorder. HLH as a preceding diagnosis to leukemia is rare. We report two cases with progression to acute leukemia, one heterozygous for MUNC13-4 and the other with reduced natural killer (NK) cell function and perforin expression. These defects may predispose to a secondary HLH-like presentation of pre-clinical leukemia or confer increased susceptibility to malignancy. HLH patients with genetic mutations or NK cell function abnormalities need monitoring for future malignancy even if the HLH resolves.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21370424&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059114/pdf/nihms234116.pdf
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectHeterozygote
dc.subjectHumans
dc.subjectKiller Cells, Natural
dc.subjectLeukemia, Monocytic, Acute
dc.subjectLymphohistiocytosis, Hemophagocytic
dc.subjectMembrane Proteins
dc.subjectMutation
dc.subjectPerforin
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subjectPrognosis
dc.subjectQa-SNARE Proteins
dc.subjectHematology
dc.subjectOncology
dc.subjectPediatrics
dc.titleHemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia
dc.typeJournal Article
dc.source.journaltitlePediatric blood and cancer
dc.source.volume56
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_hematology/133
dc.identifier.contextkey2796624
html.description.abstract<p>Hemophagocytic lymphohistiocytosis (HLH) is a rare histiocytic reactive process due to mutations in the perforin, MUNC13-4 or syntaxin 11 genes, or secondary to malignancy, infection or autoimmune disorder. HLH as a preceding diagnosis to leukemia is rare. We report two cases with progression to acute leukemia, one heterozygous for MUNC13-4 and the other with reduced natural killer (NK) cell function and perforin expression. These defects may predispose to a secondary HLH-like presentation of pre-clinical leukemia or confer increased susceptibility to malignancy. HLH patients with genetic mutations or NK cell function abnormalities need monitoring for future malignancy even if the HLH resolves.</p>
dc.identifier.submissionpathpeds_hematology/133
dc.contributor.departmentDepartment of Pathology
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages856-8


This item appears in the following Collection(s)

Show simple item record